John,
This thread is not very active, but many investors/followers of GNLB are commenting elsewhere on other threads about Genelabs' fine TA indicators and company fundamentals. Recent news releases have sparked interest and the bio sector in general has been sizzling. Additionally, of course, is the anticipation of news regarding the FDA New Drug Application filing....along with the following conference presentation schedule from Genelabs website:
genelabs.com
February
First Presentation of "GL701 Improves or Stabilizes Disease Activity in SLE" at Autoimmunity: 2000 and Beyond Conference
Genelabs' data from its second pivotal study of GL701, its investigational drug for systemic lupus erythematosus (SLE), will be presented for the first time at the Eighth International Conference on Lymphocyte Activation and Immune Regulation. The scientific conference, entitled Autoimmunity: 2000 and Beyond, is being held in Newport Beach, California on February 11-13. The results of this double-blind, placebo-controlled, randomized study in 381 women with SLE will be presented on February 13 by Philip J. Mease, M.D., an Associate Clinical Professor at the University of Washington and a rheumatologist at Minor and James Research Center in Seattle. |
